Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases/Diagnoses Clear all
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

NCT02466386
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPD489
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
50
States / cities
Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas

NCT01222754
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, High Grade Glioma
Interventions
Lenalidomide, XRT, 54-59.4 Gy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2022 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional

The Impact of Art Therapy on the Relationships Between Individuals Diagnosed With Alzheimer's Disease and Their Care Partners

NCT06725251
View directory record Official record
Conditions
Dementia
Interventions
Art Therapy
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 22, 2026, 11:07 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Advanced Ultrasound Signal Processing of Suspicious Breast Images

NCT07206888
View directory record Official record
Conditions
Breast Cancer, Breast Cyst, Microcalcification
Interventions
Imaging
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2037
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 11:07 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

NCT06812988
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Columbus, Georgia • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 11:07 PM EDT
Withdrawn Phase 4 Interventional

Blood Pressure Lowering in Acute Stroke Trial

NCT01400256
View directory record Official record
Conditions
Stroke, Acute
Interventions
Valsartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis

NCT00001946
View directory record Official record
Conditions
Atherosclerosis
Interventions
Magnetic resonance angiography
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 11:07 PM EDT
Terminated Phase 4 Interventional

Both Exercise and Adenosine Stress Testing

NCT00200629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
Procedure
Lead sponsor
Midwest Heart Foundation
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
20
States / cities
Tucson, Arizona • Roseville, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Jul 22, 2026, 11:07 PM EDT
Active, not recruiting Not applicable Interventional

MRI in Diagnosing Solid Tumors of the Eye and Orbit

NCT01653080
View directory record Official record
Conditions
Eye Cancer
Interventions
dynamic contrast-enhanced MRI
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 22, 2026, 11:07 PM EDT
Completed No phase listed Observational

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 11:07 PM EDT
Active, not recruiting Not applicable Interventional

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

NCT01266096
View directory record Official record
Conditions
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions
PET scan with 124I-cRGDY-PEG-dots
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 11:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)

NCT07277582
View directory record Official record
Conditions
Long QT Syndrome (LQTS) 2
Interventions
baseline lead-in, THRV-1268
Other · Drug
Lead sponsor
Thryv Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 11:07 PM EDT
Terminated Phase 4 Interventional

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

NCT03490396
View directory record Official record
Conditions
Oral Mucositis
Interventions
Gelclair, First® Mouthwash BLM
Device · Combination Product
Lead sponsor
Midatech Pharma US Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Jul 22, 2026, 11:07 PM EDT
Completed No phase listed Observational

Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging

NCT01434043
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Disease, Myocardial Infarction
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 11:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

4R for Guideline Indicated BRCA Testing of Breast Center Patients

NCT01320540
View directory record Official record
Conditions
Newly Diagnosed Carcinoma of Breast, Genetic Predisposition to Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00553150
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
everolimus, temozolomide, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
178
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 115 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

NCT02273596
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

NCT02309723
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Beta amyloid imaging
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Not applicable Interventional Results available

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

NCT00594815
View directory record Official record
Conditions
Lymphoma
Interventions
Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Early Phase 1 Interventional

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

NCT01980823
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Cancer of Breast
Interventions
Metformin, Atorvastatin, Breast surgery
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jul 22, 2026, 11:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability of an Algorithm to Diagnose Spasticity

NCT01644123
View directory record Official record
Conditions
Spasticity
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 100 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
3
States / cities
Murfreesboro, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Jul 22, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Results available

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

NCT01101880
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Untreated Adult Acute Myeloid Leukemia, Myeloproliferative Neoplasm With 10% Blasts or Higher
Interventions
filgrastim, clofarabine, cytarabine
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Duarte, California • Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 22, 2026, 11:07 PM EDT